Premium
Adjunctive Benefits of Systemic Etoricoxib in Non‐Surgical Treatment of Aggressive Periodontitis: Short‐Term Evaluation
Author(s) -
Azoubel Maria Cecília F.,
Sarmento Viviane A.,
Cangussú Virna,
Azoubel Eduardo,
Bittencourt Sandro,
Cunha Fernando Q.,
Ribeiro Ronaldo A.,
Brito Gerly Anne C.
Publication year - 2008
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2008.080019
Subject(s) - etoricoxib , medicine , placebo , scaling and root planing , periodontitis , bleeding on probing , dentistry , chronic periodontitis , gingival recession , statistical significance , gastroenterology , alternative medicine , pathology
Background: This pilot study assessed the effect of short‐duration treatment with etoricoxib as adjuvant therapy to scaling and root planing (SRP) on the clinical and radiographic parameters and prostaglandin E 2 (PGE 2 ) levels in aggressive periodontitis. Methods: Subjects were randomly allocated to test or control treatment (n = 10 in each group) and submitted to SRP and treatment with etoricoxib, 120 mg/day, or placebo for 7 days. Probing depth, clinical attachment level (CAL), gingival recession, visible plaque index, bleeding on probing, linear distance (LD) from the cemento‐enamel junction to the alveolar crest, and analysis of the gray levels were recorded before and 1 month after the therapies. The prostaglandin E 2 (PGE 2 ) level in the gingival crevicular fluid (GCF) was measured by radioimmunoassay at the beginning of the study and 7 and 30 days after treatment. Results: No significant difference in the clinical parameters was observed between the groups at the end of the experimental period, although both groups presented significant improvement in all variables examined. There was a decrease in CAL from 5.54 ± 0.47 mm to 3.59 ± 0.53 mm in the test group and from 5.92 ± 1.10 mm to 3.69 ± 0.80 mm in the control group. A significant reduction in PGE 2 was found after 7 days of treatment. LD differed between the groups. Conclusion: Etoricoxib did not promote additional improvement in the clinical parameters; however, it produced an initial reduction in the PGE 2 levels in the GCF, which could be related to the discrete improvement in the bone condition.